CG 026806Alternative Names: CG026806; CG’806
Latest Information Update: 15 Jun 2016
At a glance
- Originator CrystalGenomics
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Aurora kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies